Search clinical trials for: Pegylated interferon alfa-2a Ribavirin

Total 1191 results

Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Hepatitis C

Australia, Canada, France, Italy, Poland, United Kingdom, Germany, United States, Spain, Israel, Argentina, Puerto Rico, Austria
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

Chronic Hepatitis C

United States, Puerto Rico
Karolinska Institutet
The Swedish Research Council; Hoffmann-La Roche

Completed

Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment (DICO)

Chronic Hepatitis C | Human Immunodeficiency Virus

Sweden
French National Agency for Research on AIDS and...
Hoffmann-La Roche

Completed

Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)

Chronic Hepatitis C

Egypt
University College London Hospitals

Completed

Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication

Chronic Hepatitis C, HCV Genotype 1

United Kingdom
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)

Hepatitis B, Chronic
Queen Mary University of London
Nottingham University Hospitals NHS Trust; Barts & The London NHS Trust; Janssen-Cilag... and other collaborators

Completed

Telaprevir in Genotype 3 HCV (TIG3)

Hepatitis C

United Kingdom
BioGeneric Pharma
Xiamen Amoytop Biotech Co., Ltd.

Unknown

Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C

Hepatitis C | Self Efficacy

Egypt
King Abdulaziz Medical City
King Faisal Specialist Hospital & Research Center; Riyadh Military Hospital

Completed

Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients

Chronic Hepatitis C | Renal Transplant

Saudi Arabia
University Hospital Tuebingen
Dermatologic Cooperative Oncology Group

Completed

Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB

Melanoma

Germany
Hoffmann-La Roche

Completed

APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin

Hepatitis C, Chronic

Canada
Hoffmann-La Roche

Completed

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Renal Cell Carcinoma | Chronic Myelogenous Leukemia | Malignant Melanoma

Canada, India, Bulgaria, Russian Federation, Spain, South Africa, Slovakia
PV-Nord

Completed

Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera

Polycythemia Vera

France
Chinese University of Hong Kong
Hoffmann-La Roche

Completed

Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment

Chronic Hepatitis B

China
M.D. Anderson Cancer Center
Vertex Pharmaceuticals Incorporated

Terminated

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Infection

United States
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Chronic Hepatitis C

Austria, France, Germany, United Kingdom
GlaxoSmithKline
PPD

Completed

Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C, Chronic

Puerto Rico, United States
The Wistar Institute
National Institute of Allergy and Infectious Diseases (NIAID); Hoffmann-La... and other collaborators

Completed

Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection

HIV Infections

United States
ANRS, Emerging Infectious Diseases
Roche Pharma AG

Completed

ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV (ETOC)

Hepatitis

France
University of Southern California

Terminated

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

Thrombocytopenia | Hepatitis C Infection

United States
José Antonio Carrion
Instituto de Salud Carlos III

Completed

HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients

Chronic Hepatitis B (HBeAg-negative)
Cairo University
Egyptian Railway Hospital

Completed

Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)

Chronic Hepatitis c

Egypt
Hanyang University
Roche Pharma AG

Unknown

Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B. (POTENT)

Hepatitis B, Chronic

Korea, Republic of
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy

Hepatitis C, Chronic

Japan
Hoffmann-La Roche

Completed

A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)

Hepatitis D, Chronic

Romania
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C

Chronic Hepatitis C

Taiwan
Bristol-Myers Squibb

Completed

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Hepatitis C Virus

Australia, United States, Canada, France, Denmark, Italy
Bristol-Myers Squibb

Completed

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) (Hallmark DUAL)

Hepatitis C Virus

France, Germany, Korea, Republic of, Spain, Taiwan, United States, Canada, Australia, Russian Federation, Austria, Israel, Italy, Netherlands, Argentina, Poland, United Kingdom, Ireland, New Zealand
Melbourne Health
Hoffmann-La Roche; Monash University; The University of New South Wales; St Vincent... and other collaborators

Completed

Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy

Chronic Hepatitis C

Australia
GlobeImmune

Completed

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

Genotype 1 Chronic Hepatitis C

United States
Hospices Civils de Lyon

Unknown

RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin (RIBAJUSTE)

Chronic Hepatitis C

France
Bristol-Myers Squibb

Terminated

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

Hepatitis C

United States
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

Hepatitis C

United States, Canada, Germany, Puerto Rico, Spain
Hoffmann-La Roche
Roche Pharma AG

Completed

Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection

Hepatitis C, Chronic

Germany
Human Genome Sciences Inc.
Novartis

Completed

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients

Chronic Hepatitis C

United States, Spain, Canada, France, Australia, Italy, Israel, Poland, United Kingdom, Germany, Czech Republic, Romania, Austria, India, Puerto Rico
John Mascarenhas
Roche Pharma AG; The Leukemia and Lymphoma Society

Completed

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Polycythemia Vera | Essential Thrombocythemia

United States
Beijing Ditan Hospital

Completed

HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated

Chronic Hepatitis B

China
King Abdulaziz Medical City

Completed

Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4

Chronic Hepatitis C Virus

Saudi Arabia
M.D. Anderson Cancer Center

Completed

Pegasys® in Patients With Myeloproliferative Diseases

Myeloproliferative Disorders

United States
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Completed

Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Hepatitis C Virus Genotype 4 Infection

France
Arbutus Biopharma Corporation

Active, not recruiting

Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

Chronic Hepatitis b

United States, Korea, Republic of, Hong Kong, Taiwan, Australia, Moldova, Republic of, Ukraine
Johns Hopkins Bloomberg School of Public Health
National Institute on Drug Abuse (NIDA); YR Gaitonde Centre for AIDS Research...

Completed

Directly Observed Therapy for HCV in Chennai, India (C-DOT)

Hepatitis C, Chronic

India
Bristol-Myers Squibb

Completed

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Hepatitis C

France, United Kingdom, Spain, United States, Italy, Puerto Rico, Greece
Bristol-Myers Squibb

Completed

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients (HEPCAT)

Hepatitis C Virus

Australia, Sweden, United States, Canada, France, Germany, Denmark, Mexico, Italy, Puerto Rico, Egypt
Sheba Medical Center

Unknown

Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.

Chronic Hepatitis C
Human Genome Sciences Inc.
Novartis

Completed

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Chronic Hepatitis C

Korea, Republic of, United States, Spain, Canada, France, Australia, Israel, Singapore, Thailand, Malaysia, Sweden, Belgium, Germany, Taiwan, Poland, Argentina, India, Puerto Rico, Brazil, Mexico, United Kingdom
Albert Einstein College of Medicine
National Institute on Drug Abuse (NIDA)

Completed

Directly Observed Hepatitis C Treatment in Methadone Clinics

Hepatitis C | Medication Adherence

United States
Bristol-Myers Squibb

Completed

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Chronic Hepatitis C

France, United States, Puerto Rico
Vertex Pharmaceuticals Incorporated
Tibotec, Inc

Completed

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

Hepatitis C

United States, France, United Kingdom, Germany, Canada, Netherlands, Austria, Puerto Rico
Emory University
CURE Childhood Cancer, Inc.

Completed

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

Juvenile Pilocytic Astrocytomas | Optic Pathway Gliomas

United States

Search clinical trials for: Pegylated interferon alfa-2a Ribavirin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations